Clinical Trials Sponsored by Oklahoma Blood Institute

Total 4226 results

Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Hemophilia B

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Minimal Residual Disease | Bone Marrow Transplant | Ph+ ALL

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Minimal Residual Disease

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly (SAA)

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Acute Myeloid Leukemia | Measurable Disease

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital

Recruiting

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Acute Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

Chronic Lymphocytic Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Completed

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

COVID-19

China
Institute of Hematology & Blood Diseases Hospital

Terminated

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (LODACA)

Refractory Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Completed

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Acute,Leukemia, Lymphoid

China
Institute of Hematology & Blood Diseases Hospital

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

AML

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria (PNH-2012)

Urination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,

China
University of Oklahoma
National Institutes of Health (NIH); National Institute of General Medical...

Completed

CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19)

COVID-19 | Vaccine Refusal

United States
University of Oklahoma
National Institutes of Health (NIH); National Institute of General Medical...

Completed

Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations (CATCH-UP)

Covid19

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia (2023CD20ITP)

Immune Thrombocytopenia | Treatment

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Anti-CD38 Antibody Treating APS With Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Peripheral T Cell Lymphoma | Epigenetic Repression

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

Hemophilia B

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of FVIII Gene Therapy for Hemophilia A

Hemophilia A

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Refractory Hodgkin Lymphoma | Relapse | Hodgkin Lymphoma, Adult

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Connective Tissue Diseases | Autoantibodies | Immune Thrombocytopenia (ITP) | Evan Syndrome

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years (ITP)

Primary Immune Thrombocytopenic Purpura

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Gene Therapy for Chinese Hemophilia A (HA)

Hemophilia A | Gene Therapy

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Multiple Myeloma | Plasma Cell Leukemia | Extramedullary Plasmacytoma | Loss of Chromosome 17p | t(14;16) | t(4;14) | Complex Karyotype | T(14;20) | 1Q21 Amplification

China
Institute of Hematology & Blood Diseases Hospital

Unknown

EDOCH Alternating With DHAP for New Diagnosed Younger MCL (BDH-MCL01)

Mantle Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (BDH-WM01)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (BDH-WM02)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Urination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,

China
University of Oklahoma
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Expansion to Interdisciplinary HIV Prevention in Women

HIV | AIDS | Fetal Alcohol Syndrome | Alcohol Related Neurodevelopmental Disorder

United States, Russian Federation
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation

COVID-19 | Hematopoietic Stem Cell Transplantation

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Follicular Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia

Aplastic Anemia | Platelet Transfusion Refractoriness

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Hemophilia B

Clinical Trials Sponsored by Oklahoma Blood Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations